Hao Yang, Lingfei Zhao, Weiwei Kong, Shanshan Liu, Qin Zhou, Xiabing Lang, Lan Lan, Yucheng Wang
{"title":"USP18 promotes ferroptosis in lipopolysaccharide-induced human kidney organoids by stabilizing STING1.","authors":"Hao Yang, Lingfei Zhao, Weiwei Kong, Shanshan Liu, Qin Zhou, Xiabing Lang, Lan Lan, Yucheng Wang","doi":"10.1007/s10565-025-10078-8","DOIUrl":null,"url":null,"abstract":"<p><p>Sepsis-induced acute kidney injury (SI-AKI) is a severe condition with limited therapeutic options, resulting in poor prognosis. Ferroptosis exacerbates the damage caused by SI-AKI, but the mechanisms regulating ferroptosis, especially those involving ubiquitination regulators, remain poorly understood. Here, we used a lipopolysaccharide (LPS)-induced human kidney organoid (HKO) model to investigate ferroptosis in SI-AKI. RNA sequencing (RNA-seq) analysis of control and LPS-treated HKOs revealed USP18 as the only upregulated ubiquitin-specific protease (USP) in response to LPS. Further investigations showed that depletion of USP18 significantly reduced ferroptosis in LPS-induced HKOs. To explore the mechanism underlying USP18's pro-ferroptotic role, we screened four ferroptosis-related drivers and identified STING1 as the key interacting protein with USP18. Mechanistically, USP18 directly binds to STING1, deubiquitinates it, and prevents its proteasomal degradation in HKOs. Overexpression of STING1 in USP18-deficient HKOs exacerbated ferroptosis, indicating that STING1 is crucial for mediating USP18's ferroptosis-promoting function in LPS-induced HKOs. Together, these findings establish that USP18-STING1 axis plays role in LPS-induced ferroptosis in HKOs, illuminating that targeting USP18-STING1 could provide neoteric therapeutic approach for treating SI-AKI.</p>","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":"41 1","pages":"126"},"PeriodicalIF":5.9000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367870/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-025-10078-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sepsis-induced acute kidney injury (SI-AKI) is a severe condition with limited therapeutic options, resulting in poor prognosis. Ferroptosis exacerbates the damage caused by SI-AKI, but the mechanisms regulating ferroptosis, especially those involving ubiquitination regulators, remain poorly understood. Here, we used a lipopolysaccharide (LPS)-induced human kidney organoid (HKO) model to investigate ferroptosis in SI-AKI. RNA sequencing (RNA-seq) analysis of control and LPS-treated HKOs revealed USP18 as the only upregulated ubiquitin-specific protease (USP) in response to LPS. Further investigations showed that depletion of USP18 significantly reduced ferroptosis in LPS-induced HKOs. To explore the mechanism underlying USP18's pro-ferroptotic role, we screened four ferroptosis-related drivers and identified STING1 as the key interacting protein with USP18. Mechanistically, USP18 directly binds to STING1, deubiquitinates it, and prevents its proteasomal degradation in HKOs. Overexpression of STING1 in USP18-deficient HKOs exacerbated ferroptosis, indicating that STING1 is crucial for mediating USP18's ferroptosis-promoting function in LPS-induced HKOs. Together, these findings establish that USP18-STING1 axis plays role in LPS-induced ferroptosis in HKOs, illuminating that targeting USP18-STING1 could provide neoteric therapeutic approach for treating SI-AKI.
期刊介绍:
Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.